Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate

Attardo-Parrinello, Giuseppe

doi:10.1001/archinte.147.9.1629

Cited by 14 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the antiresorptive effects of alendronate (ALN) have been demonstrated over a wide range of osteolytic bone disorders [16][17][18][19], the structural consequences of its long-term use have yet to be determined. With this in mind, we investigated the effects of long-term ALN therapy, given throughout skeletal growth, maturation, and aging, on the structural and morphologic properties of rat vertebrae and femora.…”

mentioning

confidence: 99%

Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties

et al. 1993

View full text Add to dashboard Cite

Alendronate (4-amino-1-hydroxybutylidene bisphosphonate) is a novel amino bisphosphonate that is being developed for the treatment of osteolytic bone disorders such as osteoporosis. As part of a 2-year carcinogenicity study, we investigated the morphologic and biomechanical effects of long-term alendronate (ALN) therapy, given throughout skeletal growth, maturation, and aging, on rat vertebrae and femora. Three treatment groups, receiving either deionized water, low- (1.00 mg/kg), or high-dose (3.75 mg/kg) ALN, were given daily oral treatment for 105 weeks. Results from mechanical tests indicate that ALN therapy (in males) increased the vertebral ultimate compressive load by 96% in the high- and 51% in the low-dose groups when compared with controls. ALN similarly increased the male ultimate femoral bending load by 59% in the high- and 31% in the low-dose groups. Vertebrae and femora from female rats treated with both high- and low-dose ALN also failed at significantly higher loads than controls, but no differences were seen between low- and high-dose groups. Morphologic analysis of both male and female vertebrae revealed a dose-dependent increase in area fraction of bone. Rats receiving high-dose ALN had a greater area fraction of bone than those receiving low doses. Both groups were greater than controls. Thus, the administration of ALN resulted in increased femoral cortical bending load when compared with control animals, as well as increased vertebral ultimate compressive load commensurate with a dose-related preservation of vertebral bone.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

mentioning

confidence: 99%

Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties

et al. 1993

View full text Add to dashboard Cite

show abstract

“…Placebo was not used. Since our previous experience (Attardo-Parrinello et al, 1987) indicated that Clodronate is effective at least in reducing bone pain, we did not consider it ethical to ask the control patients, many of whom suffered from severe pain, to come to the day hospital for the intravenous injection of saline (placebo) for seven days and then continue it intramuscularly for another 10 days.…”

Section: Clodronate Treatmentmentioning

confidence: 99%

“…The clinical manifestations of myeloma bone disease: pain, pathological fractures and hypercalcemia, account for most of the morbidity associated with multiple myeloma (Kyle, 1975). Myelomatous hypercalcemia can be treated effectively with bisphosphonates (Paterson et al, 1983;Attardo-Parrinello et al, 1987;Canfield et al, 1987;Urwin ef al., 1987). These compounds are potent inhibitors of bone resorption.…”

Section: Introductionmentioning

confidence: 99%

Long‐term Effects of Parenteral Dichloromethylene Bisphosphonate (Cl2mbp) on Bone Disease of Myeloma Patients Treated With Chemotherapy

Merlini

Parrinello

Piccinini

et al. 1990

Hematological Oncology

View full text Add to dashboard Cite

Data on the long-term treatment of myeloma bone disease with bisphosphonates are scanty. In a prospective pilot trial we evaluated the effect of long-term parenteral administration of dichloromethylene bisphosphonate (Clodronate), in addition to standard chemotherapy, in 30 patients with active myeloma bone disease. Patients were treated with a mean of 4 courses (range 2-8) of Clodronate: 300 mg/day i.v. for seven days followed by 100 mg/day i.m. for 10 days, administered at a mean interval of 4 months (range 3-6). The median follow-up was 24 months (range 8-36). Clodronate reduced bone pain rapidly and significantly, and reduced the mean values of the biochemical indices of bone resorption to within normal limits; these effects were maintained throughout the follow-up. In three hypercalcemic episodes serum calcium became normal after 2-5 days of treatment with Clodronate. No toxic or side effects were noticed. The occurrence of skeletal morbidity in patients treated with Clodronate was compared with that observed in the control group of myeloma patients (p less than 0.001) in severe bone pain as well as in the incidence of new osteolytic lesions and pathological fractures (p less than 0.001). Supportive Clodronate therapy contributes significantly in controlling the progression of myeloma bone disease.

show abstract

“…4). 39 The major drawback of this study is its open design and the lack of a placebo, which may overestimate the analgesic effect. Palliative radiotherapy has a role in the management of refractory bone pain, usually in patients with disabling pain from a well defined focus that has failed to respond to chemotherapy.…”

Section: Bone Painmentioning

confidence: 99%

Bisphosphonates in multiple myeloma

Kanis¹,

McCloskey²

2000

Cancer

View full text Add to dashboard Cite

Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate

Cited by 14 publications

References 0 publications

Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties

Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties

Long‐term Effects of Parenteral Dichloromethylene Bisphosphonate (Cl2mbp) on Bone Disease of Myeloma Patients Treated With Chemotherapy

Bisphosphonates in multiple myeloma

Contact Info

Product

Resources

About